• PLGA Nano-Adjuvant Targets Intestinal Immunity in Chicks

  2026-09-14

  A 2026 Poultry Science study developed PEI-LSP-RA-PLGA, a layered PLGA nanoparticle adjuvant designed to combine sustained delivery with intestinal immune targeting in chicks receiving an inactivated H9N2 vaccine. The formulation enhanced systemic IgG and intestinal IgA responses and was associated with CCR9/CCR6, Toll-like receptor, NOD-like receptor, and IgA-production pathways.

• GMA, Neuroinflammation, and Rapid Antidepressant Effects

  2026-09-14

  A Journal of Ethnopharmacology study identifies GMA, a refined combination of Gardeniae Fructus, Moutan Cortex, and Angelica Sinensis Radix, as a rapidly acting antidepressant-like formula in LPS-treated mice. The findings connect behavioral improvement with reduced hippocampal neuroinflammation and restoration of CaMKII–mTOR–BDNF neuroplasticity signaling, while also defining important limits for translation beyond the animal model.

• IWP-2 Wnt Production Inhibitor Workflow

  2026-09-13

  IWP-2 enables upstream control of Porcupine-dependent Wnt secretion for cancer research, pathway validation, and mechanism-focused phenotyping. This practical guide connects concentration selection, apoptosis assay design, and single-nucleus profiling concepts to improve reproducibility without overstating translational evidence.

• TSA and Tumor Immunogenicity: A Translational Lens

  2026-09-12

  Trichostatin A offers a reversible way to interrogate how HDAC-dependent chromatin repression shapes cancer-cell behavior and tumor immunogenicity. This thought-leadership guide connects TSA pharmacology with the CBX2–RACK1–HDAC1 axis, outlining validation strategies, experimental safeguards, and translational boundaries for cancer research.

• (-)-Blebbistatin and Atrial Conduction

  2026-09-11

  Discover how (-)-Blebbistatin, a reversible non-muscle myosin II inhibitor, can help separate electromechanical contributions to atrial conduction heterogeneity. This article translates dynamic optical-mapping findings into practical assay design, controls, and interpretation strategies.

• Epalrestat Workflows for Neuroprotection Research

  2026-09-11

  Epalrestat gives researchers a practical way to connect aldose reductase inhibition, polyol pathway inhibition, and KEAP1/Nrf2-linked antioxidant responses in cell and animal models. This workflow-focused guide covers model selection, dosing logic, assay controls, solubility management, and troubleshooting for diabetic neuropathy research and Parkinson’s disease model studies.

• Carbapenemase Gene Transmission in CREC

  2026-09-10

  This 2025 BMC Microbiology study integrates carbapenemase-gene localization, conjugative transfer, mobile-element profiling, and strain typing in 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals. Its central finding is the combination of high carbapenemase-gene prevalence and efficient laboratory transfer, highlighting why plasmid surveillance is essential for the study of antibiotic resistance mechanisms.

• GSK J4 HCl: From Chromatin Mechanism to Translation

  2026-09-10

  GSK J4 HCl offers translational researchers a cell-permeable way to interrogate JMJD3-dependent chromatin regulation across inflammation and cancer models. This thought-leadership article connects the compound’s macrophage and xenograft evidence with a mechanistic framework inspired by human decidual CXCL10 regulation, while defining practical validation gates and important limits on cross-model interpretation.

• Polystyrene Nanoplastics, NMNAT3, and Fetal Growth

  2026-09-09

  A 2026 study identifies an NMNAT3-dependent pathway linking gestational polystyrene nanoplastic exposure to placental NAD+ depletion, mitochondrial dysfunction, ferritinophagy, and ferroptosis. Its integrated metabolomic, animal, and trophoblast experiments highlight nicotinamide metabolism as a potential intervention point while defining important limits for translation to other injury models.

• Vorinostat, HDAC Signaling, and Programmed Death

  2026-09-09

  Vorinostat research is entering a more precise phase: separating HDAC target engagement, transcriptional remodeling, and apoptosis. Building on the 2025 Cell study of RNA Pol II degradation-dependent apoptosis, this article outlines a translational framework for using Vorinostat (SAHA, MK0683) in cancer biology research, epigenetic modulation, and mechanistic cell-death studies.

• Apicidin: HDAC Inhibition for Reproducible Assays

  2026-09-08

  Apicidin is a potent histone deacetylase inhibitor for connecting HDAC activity with chromatin, proliferation, angiogenesis, and oocyte-quality endpoints. This workflow-focused guide shows how to build dose-response assays, manage limited solubility, and translate the latest meiotic findings into reproducible bench experiments.

• EdU Imaging Kits (Cy3) for S-Phase Assays

  2026-09-08

  EdU Imaging Kits (Cy3) deliver denaturation-free visualization of DNA synthesis for microscopy and flow cytometry. They are especially useful for linking oncogenic signaling, drug response, and cell-cycle behavior without sacrificing morphology or antigen accessibility.

• 3-Hydroxybutyrate (BHBA): Mechanisms and Research Use

  2026-09-07

  3-hydroxybutyrate (BHBA) is an endogenous ketone body and metabolic signal that links fatty acid utilization with membrane, ferroptosis, and chromatin biology. The strongest stroke evidence currently supports ketone-body involvement in remote ischemic postconditioning, while direct attribution to purified BHBA remains an experimental question.

• Panobinostat Workflow for Reproducible Drug Response

  2026-09-07

  Build a Panobinostat workflow that separates growth inhibition from true cell killing, then links HDAC activity to apoptosis and chromatin responses. The approach is designed for multiple myeloma, leukemia, and drug-resistant breast cancer models where a single viability endpoint can obscure treatment biology.

• Faropenem Sodium and Antimicrobial Resistance

  2026-09-05

  Dharmapalan and Chandy examine faropenem as an orally convenient penem antibiotic whose expanding use may create stewardship risks, including possible cross-resistance with carbapenems. The article’s central contribution is to connect regulatory status, consumption trends, missing susceptibility breakpoints, and rational prescribing rather than treating broad antibacterial activity as evidence for routine use.

8645 records 1/577 page Next 12345 下5页 Last page